GlassScriptPhysician profile
Neil Pugach
NPI 1689675258
$244,204.32
in general payments reported to CMS, 2019-2025
16 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $71K · 2021: $43K · 2022: $40K · 2023: $7,870 · 2024: $4,142 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $2,498 · Consulting Fee: $1,525 · Travel and Lodging: $619 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,345.00 |
| Food and Beverage | $2,498.40 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $618.57 |
| Education | $217.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72,128.84 | 2019-2023 | Emgality |
| Amgen INC. | $52,484.00 | 2019-2023 | Aimovig |
| Abbvie INC. | $34,669.49 | 2021-2025 | |
| Allergan, INC. | $32,456.89 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $26,706.47 | 2019-2025 | Ajovy |
| Pfizer INC. | $15,081.90 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $4,549.74 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,276.27 | 2022 | |
| Lundbeck LLC | $2,161.95 | 2020-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $295.88 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $120.51 | 2020-2022 | |
| Impel Pharmaceuticals LLC | $77.89 | 2025 | Trudhesa |
| Upsher-Smith Laboratories LLC | $71.47 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $67.43 | 2021 | |
| Collegium Pharmaceutical, INC. | $30.30 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $25.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Pugach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.